Company intelligence / Profile preview

Genocury Biotech

Shenzhen, Guangdong Sheng, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Genocury recently announced groundbreaking clinical data from its novel in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). In an investigator-initiated trial led by Tongji Hospital, a heavily pretreated R/R patient with advanced DLBCL achieved complete remission (CR) after 1 month of treatment, with durable response sustained over three months. The therapy eliminated the need for lymphodepletion, a standard yet toxic preconditioning step in traditional CAR-T protocols.[5][6]

Therapeutic areas: OncologyHematology
Modalities: Cell therapyGene therapyCAR-TCAR-NKiPSC (induced pluripotent stem cells)
Industry: Biotech

Drug pipeline

3 assets

JY231

2 more assets in the full pipeline.

Request access →

Partnerships

Tongji Hospital (for clinical trials)

Beyond the preview

Go deeper on Genocury Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genocury Biotech.

Explore the full profile